Recursion Pharmaceuticals, Inc. (RXRX) — 10-Q Filings
All 10-Q filings from Recursion Pharmaceuticals, Inc.. Browse 6 Quarterly Report reports with AI-powered summaries and risk analysis.
10-Q Filings (6)
-
Recursion's Losses Widen Amid Soaring R&D Spend
— Nov 5, 2025 Risk: high
Recursion Pharmaceuticals, Inc. (RXRX) reported a significant increase in net loss for the nine months ended September 30, 2025, reaching $536.6 million, a subs -
Recursion Pharma's Revenue Soars, But Net Losses Widen to $105.3M
— Aug 5, 2025 Risk: high
RECURSION PHARMACEUTICALS, INC. reported total revenue of $10.1 million for the three months ended June 30, 2025, a significant increase from $5.2 million for t -
Recursion Pharma Q1 Revenue Dips Amid R&D Focus
— May 5, 2025 Risk: medium
Recursion Pharmaceuticals, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported license and service revenue of $1.7 million for Q1 202 -
Recursion Pharmaceuticals Files Q3 2024 10-Q
— Nov 6, 2024 Risk: medium
Recursion Pharmaceuticals, Inc. filed a 10-Q for the period ending September 30, 2024. The filing details their financial performance and business operations. K -
Recursion Pharmaceuticals Files Q2 2024 10-Q
— Aug 8, 2024 Risk: medium
Recursion Pharmaceuticals, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported its financial results and operational highlights. Key f -
Recursion Pharmaceuticals, Inc. Files 10-Q for Period Ending March 31, 2024
— May 9, 2024 Risk: medium
RECURSION PHARMACEUTICALS, INC. (RXRX) filed a Quarterly Report (10-Q) with the SEC on May 9, 2024. Recursion Pharmaceuticals, Inc. filed a 10-Q report for the
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX